WendySLaneMD

Endocrinology • Asheville, NC

Diabetes, Lipid Metabolism

Endocrinologist, Mountain Diabetes/Endocrine Center

Join to view full profile

Dr. Lane is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lane's full profile

Already have an account?

Office
1998 Hendersonville Rd
Ste 3
Asheville, NC 28803
Phone+1 828-258-2404

Fax+1 828-258-0864
Is this information wrong?

Education & Training

Maine Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
Newton-Wellesley HospitalResidency, Internal Medicine, 1984 - 1987
Geisel School of Medicine at DartmouthClass of 1984

Certifications & Licensure

NH State Medical License 1987 - Present
NC State Medical License 1998 - 2025
SC State Medical License 1995 - 1998
ME State Medical License Active through 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod Start of enrollment: 2007 Dec 01
Completed
Phase 4
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics Start of enrollment: 2011 Dec 01
Completed
Phase 4
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® Start of enrollment: 2013 Oct 01
Terminated
Phase 3
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2015 Oct 20
Completed
Phase 3
The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus Start of enrollment: 2019 Mar 27
Recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

13 citations
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a...
Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S Bajaj, Wendy Lane, Ana Laura S A Matos, Sreenivasa Murthy, Karolina Stachlewska, Julio Rosenstock> ;Lancet. 2023 Jun 10
1 citations
Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial.
Wendy Lane, Elena Favaro, Esteban Jódar, Pranav Kelkar, Alejandra Oviedo, Ramsathish Sivarathinasami, Peter A Senior, Giorgio Sesti, Edward Franek> ;Diabetes Therapy. 2022 Apr 1
3 citations
Basal Insulin degludec and GLycemic control ComparEd to Aspart via insulin Pump in type 1 diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial.
Wendy Lane, Stephen L. Weinrib, Michael J. Lawrence, Benjamin C. Lane, Ryan T. Jarrett> ;Endocrine Practice. 2021 Nov 8
1 citations
Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study.
Wendy Lane, Mads Faurby, Lise Lotte N. Husemoen, Dmitriy L. Markovich, Naveen Rathor, Christophe De Block> ;Diabetes Therapy. 2021 Oct 12
7 citations
Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes
Wendy Lane, Emma Lambert, Jesso George, Naveen Rathor, Nandu Thalange> ;Clinical Diabetes. 2021 Aug 2
6 citations
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study
Thomas Blevins, Wendy Lane, David Rodbard, Dana Sindelar, Ludi Fan, Kelly Ellinor, Liza L. Ilag, Trang T. Ly, Jennal Johnson> ;Diabetes Technology & Therapeutics. 2021 Jan 1
4 citations
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
Athena Philis-Tsimikas, Wendy Lane, Ulrik Pedersen-Bjergaard, Carol Wysham, Lars Bardtrum, Signe Harring, Simon Heller> ;Diabetes, Obesity & Metabolism. 2020 Jan 24
1 citations
Comment on Feig et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Ca...
Julia M. Sacha, Wendy Lane> ;Diabetes Care. 2019 Jun 1
49 citations
A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diab...
David C. Klonoff, Mark L. Evans, Wendy Lane, Hans-Peter Kempe, Eric Renard, J. Hans DeVries, Tina Graungaard, A. Hyseni, Theis Gondolf, Tadej Battelino> ;Diabetes, Obesity & Metabolism. 2019 Apr 1
14 citations
Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A pos...
J. Hans DeVries, Timothy S. Bailey, Anuj Bhargava, Gregg Gerety, Janusz Gumprecht, Simon Heller, Wendy Lane, Carol Wysham, Bernard Zinman, Britta A. Bak, Elise Hachman...> ;Diabetes, Obesity & Metabolism. 2019 Mar 1
142 citations
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
John B. Buse, Satish K. Garg, Julio Rosenstock, Timothy S. Bailey, Phillip Banks, Bruce W. Bode, Thomas Danne, Jake A. Kushner, Wendy Lane, Pablo Lapuerta, Darren K. M...> ;Diabetes Care. 2018 Sep 1
60 citations
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.
Palmer, A. J., Si, L., Tew, M., Hua, X., Willis, M. S., Asseburg, C., McEwan, P., Leal, J., Gray, A., Foos, V., Lamotte, M., Feenstra, T., O'Connor, P. J., Brandle, M....> ;Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Jun 19
6 citations
Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables
Wendy S. Lane, James Weatherall, Jens Gundgaard, Richard F Pollock> ;Journal of Medical Economics. 2018 Feb 1
Insulin Analogues and Hypoglycemia in Patients With Type 1 Diabetes-Reply.
Wendy Lane, Timothy S. Bailey, Gregg Gerety> ;JAMA. 2017 Nov 14
155 citations
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S. Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte T. Hansen, Thor S. S. Nielsen, Mark Warren> ;JAMA. 2017 Jul 4
1 citations
SGLT-2 INHIBITORS AS ADJUNCT THERAPY IN TYPE 1 DIABETES: REASON FOR HOPE AND CAUTION
Wendy Lane> ;Endocrine Practice. 2016 Mar 1
62 citations
The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial
Wendy Lane, S. Weinrib, J. Rappaport, C. Hale> ;Diabetes, Obesity & Metabolism. 2014 Sep 1
109 citations
Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force.
George Grunberger, Jill M. Abelseth, Timothy S. Bailey, Bruce W. Bode, Yehuda Handelsman, Richard Hellman, Lois Jovanovič, Wendy Lane, Philip Raskin, William V. Tambor...> ;Endocrine Practice. 2014 May 1
43 citations
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5...
Helena W. Rodbard, Stephen C. L. Gough, Wendy Lane, Lars Korsholm, Ditte-Marie Bretler, Yehuda Handelsman> ;Endocrine Practice. 2014 Apr 1
18 citations
The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients wit...
Wendy Lane, Stephen L. Weinrib, Jonathan M. Rappaport, Christopher B. Hale, Lynley K. Farmer, Rebecca S. Lane> ;Endocrine Practice. 2013 Mar 1
Successful management of differentiated thyroid cancer in a community-based endocrine practice
Stephen L. Weinrib, Wendy Lane, Jonathan M. Rappaport> ;Endocrine Practice. 2012 Mar 1
48 citations
The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
Wendy Lane, Stephen L. Weinrib, Jonathan M. Rappaport> ;Diabetes Technology & Therapeutics. 2011 Apr 27
32 citations
A PROSPECTIVE TRIAL OF U500 INSULIN DELIVERED BY OMNIPOD IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SEVERE INSULIN RESISTANCE
Wendy Lane, Stephen L. Weinrib, Jonathan M. Rappaport, Therese Przestrzelski> ;Endocrine Practice. 2010 Sep 1
99 citations
High-dose insulin therapy: is it time for U-500 insulin?
Wendy Lane, Elaine Cochran, Jeffrey A. Jackson, Jamie Scism-Bacon, Ilene B. Corey, Irl B. Hirsch, Jay S. Skyler> ;Endocrine Practice. 2009 Jan 1
37 citations
USE OF U-500 REGULAR INSULIN BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE INSULIN RESISTANCE
Wendy Lane> ;Endocrine Practice. 2006 May 1
Join now to see all

Lectures

Updates in Individualizing Therapy in Type 2 Diabetes: Optimizing Insulin and Non-Insulin Combinations
ENDO 2019 - New Orleans, LA - 3/24/2019
Liraglutide Added to High-Dose Basal/Bolus Insulin in Type 2 Diabetes
Asheville, NC - 6/15/2014

Press Mentions

Paying the Price: Coping with the High Cost of InsulinNovember 26th, 2018